{"a":[{"_":"Merck sees pivotal victory for $3B eye disease prospect","$":{"href":"/biotech/merck-co-uncorks-pivotal-victory-3b-eye-disease-prospect","hreflang":"en"}}]}
Phase 3positiveBrunelloPositive
AI Analysis
Summary
Merck's Brunello, a trispecific DME drug candidate acquired for $3 billion, has met the primary endpoint of its pivotal trial. This positive Phase 3 result advances the therapeutic candidate toward potential regulatory submission.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Brunello trial hit primary endpoint
Importance:8/10
Sentiment:
0.80
Phase 3Primary endpoint metEye diseaseTrispecificAcquisition
Related Companies
Read the original article
Published by FierceBiotech on September 24, 2026 8:15 AM